Trial Profile
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole; Pertuzumab; Trastuzumab
- Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms AFT-38 (PATINA); PATINA
- Sponsors Alliance Foundation Trials
- 29 Jan 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Apr 2024.
- 21 Apr 2023 Planned End Date changed from 31 May 2026 to 31 Jul 2026.
- 21 Apr 2023 Planned primary completion date changed from 31 May 2023 to 30 Dec 2023.